Every S-1 that Cellectar Biosciences INC NEW (CLRB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow CLRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLRB filings page.
Cellectar Biosciences, Inc. has filed an amended S-1 to register the resale of up to 51,998,413 shares of common stock for existing selling stockholders. These shares include stock already issued in a May 2026 private placement and shares issuable upon exercise of Pre-Funded, Series A, Series B, Series C and Placement Agent Warrants.
The company will not receive proceeds from stockholder resales but may receive cash if the various warrants are exercised. After full exercise of the registered warrants, total common shares outstanding would rise to 57,856,595. The filing also details significant financing risks, including expectations of continued operating losses and substantial doubt about the company’s ability to continue as a going concern without additional capital.
Cellectar Biosciences, Inc. has filed an S-1 to register the resale of up to 51,206,051 shares of common stock by selling stockholders. These shares include stock already issued in a May 2026 private placement and shares issuable upon exercise of pre-funded and Series A, B and C warrants.
The company will not receive proceeds from stockholder resales, but could receive cash if warrants are exercised. If all warrants are exercised, shares outstanding would rise to 57,064,233 from 5,858,182 adjusted shares as of April 30, 2026. Cellectar highlights substantial regulatory, clinical and manufacturing risks around its lead cancer candidate iopofosine I 131.
As of December 31, 2025, cash was about $13.2 million, which management believes funds basic operations into the second quarter of 2027. The company warns of substantial doubt about its ability to continue as a going concern without additional capital and outlines extensive risks related to financing, approvals, competition and ongoing compliance.
Cellectar Biosciences filed an S-1 for a resale of up to 2,096,188 shares of common stock by selling stockholders. These shares are issuable upon exercise of previously issued Inducement Warrants from an October 2025 warrant inducement transaction. The company states it will not receive proceeds from selling stockholder resales; it would receive cash only if holders exercise the warrants.
The Inducement Warrants consist of two series, each immediately exercisable at $6.00 per share: Series I (up to 1,048,094 shares) expiring October 8, 2030, and Series II (up to 1,048,094 shares) expiring April 8, 2027. Cellectar previously received approximately $5.8 million gross proceeds from the cash exercise of certain existing warrants and the sale of the Inducement Warrants tied to this transaction.
As context, the company lists 6,336,322 shares outstanding after completion of this offering assuming full warrant exercise. Cellectar’s common stock trades on Nasdaq as “CLRB”; on October 17, 2025, the last reported sale price was $4.50.